Compare Biogen Inc (BIIB) vs Snap On Incorporated (SNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Snap On Incorporated — how do they compare? Biogen Inc trades at $189.48 (market cap $28.34B), while Snap On Incorporated trades at $401.99 (market cap $20.96B). The key difference: Biogen Inc is the larger of the two by market cap, and Snap On Incorporated pays a 2.41% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | SNA | |
|---|---|---|
Market Cap | $28.34B | $20.96B |
Sector | Health | Technology |
52-Week High | $216.63 | $413.62 |
52-Week Low | $122.68 | $313.01 |
Enterprise Value | $30.62B | $20.48B |
Dividend Yield | — | 2.41% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $209.03, up 4.96% today, with a bullish technical signal and strong analyst support. Recent quarterly earnings have consistently beaten expectations, and the company maintains solid profitability with a 75.49% gross margin. Key developments include FDA approval for a subcutaneous starter dose of Leqembi and promising Phase 2 data for its Alzheimer's drug diranersen, driving positive sentiment.
The outlook is positive, with a consensus price target of $230.18 suggesting upside. Investment opportunities lie in Alzheimer's pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Revenue stability and cost management support fundamentals, though regulatory hurdles remain a watchpoint.
Snap-on Incorporated (SNA) trades at $401.11, down 0.21% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong profitability with a 19.6% net income margin and ROE of 17.83%, while recent acquisitions like Diesel Laptops for $100 million aim to expand heavy-duty diagnostics capabilities. Q1 2026 earnings missed expectations slightly, but Q2 results are anticipated.
Outlook remains positive with analyst consensus favoring Buy ratings (64.71%) and a $407.50 price target, though risks include margin pressures and muted growth forecasts. The stock offers stability with consistent dividends and share repurchases, but investors should monitor competitive and economic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Snap On Incorporated
Snap-on Incorporated is a leading global innovator, manufacturer, and marketer of tools, equipment, diagnostics, repair information, and systems solutions for professional users. Its products are widely used in vehicle service and repair, as well as in other demanding industrial environments. The company is best known for its premium tool brand, often sold through a network of franchised mobile stores, and is a primary supplier to technicians in the transportation industry.
Read more on SNA →
